Evidence map›Paper›PMID 37981236›Full record

ArticleAnnals of hepatology

Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.

Siyu Fu, Dhamina Karim, Jhon Prieto, Domingo Balderramo, Javier Diaz Ferrer, Angelo Z Mattos, Marco Arrese, Enrique Carrera, Jeffrey Oliveira, Jose D Debes and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 6 countries.

Siyu FuDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Dhamina KarimSchool of Public Health, University of Minnesota, Minneapolis, MN, USA.
Jhon PrietoCentro de Enfermedades Hepaticas y Digestivas, Bogota, Distrito Capital de Bogota, Colombia.
Domingo BalderramoHospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Cordoba, Argentina.
Javier Diaz FerrerFacultad de Medicina, Universidad de San Martin de Porres, Lima, Perú.
Angelo Z MattosGraduate Program in Medicine: Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
Marco ArreseDepartamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Enrique CarreraHospital Especialidades Eugenio Espejo, Universidad San Francisco de Quito, Quito, Ecuador.
Jeffrey OliveiraDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Jose D DebesDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; School of Public Health, University of Minnesota, Minneapolis, MN, USA; Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Andre BoonstraDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Electronic address: p.a.boonstra@erasmusmc.nl.
Erasmus MC · NLUniversity of Minnesota · USHospital Privado · ARPontificia Universidad Católica de Chile · CLUniversidad de San Martín de Porres · PEUniversidad San Francisco de Quito · EC

Funding

Impact of Hepatitis C and HIV coinfection on biological aging and hepatocellular carcinoma riskR21TW012390 · FIC · UNIVERSITY OF MINNESOTA · PI DEBES, JOSE DANIEL · 2022 to 2023
$500k
FIC NIH HHS R21 TW012390
6 · The paper itself

Abstract

INTRODUCTION AND

objectivesTolloid like protein 1 (TLL1) rs17047200 has been reported to be associated with HCC development and liver fibrosis. However, to our knowledge, no studies have been performed on Latin Americans and comparative differences between TLL1 rs17047200 in HCC patients from Latin America and Europe are undefined. MATERIALS AND

methodsCross-sectional analysis was performed on Latin American and European individuals. We analyzed TLL1 rs17047200 on DNA from 1194 individuals, including 420 patients with HCC (86.0 % cirrhotics) and 774 without HCC (65.9 % cirrhotics).

resultsTLL1 rs17047200 genotype AT/TT was not associated with HCC development in Latin Americans (OR: 0.699, 95 %CI 0.456-1.072, p = 0.101) or Europeans (OR: 0.736, 95 %CI 0.447-1.211, p = 0.228). TLL1 AT/TT was not correlated with fibrosis stages among metabolic dysfunction-associated steatotic liver disease (MASLD) patients from Latin America (OR: 0.975, 95 %CI 0.496-1.918, p = 0.941). Among Europeans, alcohol-related HCC had lower TLL1 AT/TT frequencies than cirrhosis (18.3 % versus 42.3 %, OR: 0.273, 95 %CI 0.096-0.773, p = 0.015).

conclusionsWe found no evidence that the TLL1 rs17047200 AT/TT genotype is a risk factor for HCC development in Latin Americans or Europeans. A larger study integrating ethnic and etiology backgrounds is needed to determine the importance of the TLL1 SNP in HCC development.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCross-Sectional StudiesHumansLiver CirrhosisPolymorphism, Single NucleotideRisk FactorsTolloid-Like MetalloproteinasesTLL1 protein, humanTolloid-Like MetalloproteinasesCancerHepatocellular carcinomaLatin AmericaLiverTLL1

Identifiers

PMID37981236
PMCPMC13641324
OpenAlexW4388821913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.